{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T07:29:36Z","timestamp":1762068576114,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Glenmark Pharmaceuticals Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ARM"],"abstract":"<jats:p>Inhaled corticosteroid and ultra-long-acting beta-agonist (ICS\/uLABA) combination is a recent advancement in the armamentarium against obstructive airways diseases (OADs). The combination of ICS\/uLABA has several advantages, creating a favorable landscape for its utilization. Fluticasone furoate\/vilanterol trifenatate (FF\/Vi) is one such example of an ICS\/uLABA. It offers several benefits from both drugs, such as a convenient once daily dosing schedule; high lipophilicity; high receptor affinity of fluticasone furoate along with high functional selectivity and a quick onset of action of vilanterol. However, the Global Initiative for Asthma (GINA) as well as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines do not clearly define the positioning of ICS\/uLABA compared to conventional ICS\/LABAs. There are a few areas of uncertainty especially around the appropriate reliever strategy with ICS\/uLABA in Asthma. The current consensus was planned with a group of Indian pulmonology experts to provide more clarity on the potential use of FF\/Vi in Asthma and COPD. The clinical statements highlighted in this consensus manuscript address crucial clinical questions revolving around the efficacy and safety of FF\/Vi as compared to conventional ICS\/LABAs and identify the ideal patient profile for its use. This consensus paper also sheds light upon the appropriate reliever to be used along with FF\/Vi in Asthma and the utilization of FF\/Vi-based triple therapy in OADs. Expert recommendations mentioned in this paper will serve as guidance to pulmonologists as well as consultant physicians who are involved in providing care to OAD patients and will help them weigh the various factors that need to be taken into account while prescribing ICS\/uLABA combination.<\/jats:p>","DOI":"10.3390\/arm90050051","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T01:43:01Z","timestamp":1664502181000},"page":"407-424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["ICS\/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts"],"prefix":"10.3390","volume":"90","author":[{"given":"Raja","family":"Dhar","sequence":"first","affiliation":[{"name":"Department of Pulmonology, The Calcutta Medical Research Institute, Kolkata 700088, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Talwar","sequence":"additional","affiliation":[{"name":"Metro Respiratory Center, Pulmonology & Sleep Medicine, Metro Hospitals & Heart Institute, Noida 201301, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7347-5723","authenticated-orcid":false,"given":"Prince","family":"James","sequence":"additional","affiliation":[{"name":"Interventional Pulmonology Department, Naruvi Hospital, Vellore 632004, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwini","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis and Chest Medicine, Baba Raghav Das Medical College, Gorakhpur 273013, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judo","family":"Vachaparambil","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sun Medical Research Centre, Thrissur 680021, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai 400099, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishtha","family":"Khatri","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai 400099, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Bhagat","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai 400099, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai 400099, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.18553\/jmcp.2012.18.7.527","article-title":"Dosing Frequency and Medication Adherence in Chronic Disease","volume":"18","author":"Coleman","year":"2012","journal-title":"JMCP"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/COPD.S3036","article-title":"Medication adherence issues in patients treated for COPD","volume":"3","author":"Restrepo","year":"2008","journal-title":"COPD"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.112.198481","article-title":"In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting \u03b22-Adrenoceptor Agonist with 24-Hour Duration of Action","volume":"344","author":"Slack","year":"2013","journal-title":"J. Pharm. Exp."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.2147\/COPD.S170606","article-title":"LABA\/LAMA fixed-dose combinations in patients with COPD: A systematic review","volume":"13","author":"Rogliani","year":"2018","journal-title":"COPD"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2016.1192125","article-title":"Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma","volume":"12","author":"Calzetta","year":"2016","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bcp.14406","article-title":"Therapeutic index of inhaled corticosteroids in asthma: A dose\u2013response comparison on airway hyperresponsiveness and adrenal axis suppression","volume":"87","author":"Brealey","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1465-9921-12-132","article-title":"Efficacy in asthma of once-daily treatment with fluticasone furoate: A randomized, placebo-controlled trial","volume":"12","author":"Woodcock","year":"2011","journal-title":"Respir Res."},{"unstructured":"Breo Ellipta (2021, March 10). Highlights of Prescribing Information 2019, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/204275s017lbl.pdf.","key":"ref_8"},{"unstructured":"Relvar Ellipta (2021, March 11). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/relvar-ellipta-epar-product-information_en.pdf.","key":"ref_9"},{"unstructured":"(2022). Grant of Permission to Manufacture and Market FDC of Fluticaosne Furoate + Vilanterol Trifenatate eq. to Vilanterol Dry Powder for Inhalation in Capsule (Standard No. Form CT-23). Government of India.","key":"ref_10"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.rmed.2012.12.014","article-title":"A randomised trial of fluticasone furoate\/vilanterol (50\/25 \u03bcg; 100\/25 \u03bcg) on lung function in COPD","volume":"107","author":"Kerwin","year":"2013","journal-title":"Respir. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.rmed.2012.12.016","article-title":"Fluticasone furoate\/vilanterol (100\/25; 200\/25 \u03bcg) improves lung function in COPD: A randomised trial","volume":"107","author":"Martinez","year":"2013","journal-title":"Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/JAA.S223093","article-title":"Once-daily fluticasone furoate\/vilanterol combination versus twice-daily budesonide\/formoterol combination in the treatment of controlled stable asthma: A randomized crossover trial","volume":"12","author":"Furuhashi","year":"2019","journal-title":"JAA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1080\/02770903.2021.1963767","article-title":"Symptom control in patients with asthma using inhaled corticosteroids\/long-acting \u03b22-agonists (fluticasone furoate\/vilanterol or budesonide\/formoterol) in the US: A retrospective matched cohort study","volume":"59","author":"Averell","year":"2021","journal-title":"J. Asthma"},{"unstructured":"(2021, October 19). Global Strategy for Asthma Prevention Report 2021. Available online: https:\/\/ginasthma.org\/gina-reports\/.","key":"ref_15"},{"unstructured":"(2021, October 18). Global Initiative for Chronic Obstructive Lung Disease COPD Guidelines 2021. Available online: https:\/\/goldcopd.org.","key":"ref_16"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa1608033","article-title":"Effectiveness of Fluticasone Furoate\u2013Vilanterol for COPD in Clinical Practice","volume":"375","author":"Vestbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2019.01.019","article-title":"Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS\/LABA","volume":"150","author":"Stanford","year":"2019","journal-title":"Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/S0140-6736(17)32397-8","article-title":"Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: An open-label, parallel group, randomised controlled trial","volume":"390","author":"Woodcock","year":"2017","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): A double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/thx.2009.128504","article-title":"Single maintenance and reliever therapy (SMART) of asthma: A critical appraisal","volume":"65","author":"Chapman","year":"2010","journal-title":"Thorax"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.anai.2019.10.002","article-title":"Anti-inflammatory reliever therapy for asthma","volume":"124","author":"Lipworth","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106524","DOI":"10.1016\/j.rmed.2021.106524","article-title":"Asthma patients\u2019 and physicians\u2019 perspectives on the burden and management of asthma","volume":"186","author":"Chapman","year":"2021","journal-title":"Respir Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/cea.13795","article-title":"Participants of the regional meetings As-needed anti-inflammatory reliever therapy for asthma management: Evidence and practical considerations","volume":"51","author":"Bianco","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/thoraxjnl-2013-203600","article-title":"Once-daily fluticasone furoate (FF)\/vilanterol reduces risk of severe exacerbations in asthma versus FF alone","volume":"69","author":"Bateman","year":"2014","journal-title":"Thorax"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.rmed.2018.06.003","article-title":"Patient-reported outcomes with initiation of fluticasone furoate\/vilanterol versus continuing usual care in the Asthma Salford Lung Study","volume":"141","author":"Svedsater","year":"2018","journal-title":"Respir. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4104\/pcrj.2013.00091","article-title":"Continuing discrepancy between patient perception of asthma control and real-world symptoms: A quantitative online survey of 1083 adults with asthma from the UK","volume":"22","author":"Fletcher","year":"2013","journal-title":"Prim. Care Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/02770903.2019.1702674","article-title":"Once daily combined inhaled steroid and ultra long-acting bronchodilator prescribing in pediatric asthma: A dual Center retrospective cohort study","volume":"58","author":"Langley","year":"2021","journal-title":"J. Asthma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3109\/02770903.2015.1056350","article-title":"Fluticasone furoate (FF)\/vilanterol (100\/25 mcg or 200\/25 mcg) or FF (100 mcg) in persistent asthma","volume":"52","author":"Bernstein","year":"2015","journal-title":"J. Asthma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.rmed.2016.09.006","article-title":"Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate\/vilanterol inhaler in adult asthma","volume":"119","author":"Braithwaite","year":"2016","journal-title":"Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-018-0836-6","article-title":"Anti-inflammatory duration of action of fluticasone furoate\/vilanterol trifenatate in asthma: A cross-over randomised controlled trial","volume":"19","author":"Bardsley","year":"2018","journal-title":"Respir Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2021.01.027","article-title":"Inhaled long-acting muscarinic antagonists in asthma\u2014A narrative review","volume":"85","author":"Papi","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2004233","DOI":"10.1183\/13993003.04233-2020","article-title":"Triple therapy in uncontrolled asthma: A network meta-analysis of phase III studies","volume":"58","author":"Rogliani","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjmed.2021.09.006","article-title":"The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice","volume":"135","author":"Adcock","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12931-019-1262-0","article-title":"Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: A pooled analysis","volume":"21","author":"Hartley","year":"2020","journal-title":"Respir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"00282","DOI":"10.1183\/23120541.00282-2019","article-title":"Pneumonia in exacerbations of COPD: What is the clinical significance?","volume":"6","author":"Trethewey","year":"2020","journal-title":"ERJ Open Res."},{"unstructured":"(2021, December 31). EMA Completes Review of Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease 2016. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-completes-review-inhaled-corticosteroids-chronic-obstructive-pulmonary-disease.","key":"ref_40"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/15412555.2020.1787369","article-title":"Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis","volume":"17","author":"Zhang","year":"2020","journal-title":"COPD J. Chronic. Obstr. Pulm. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2040622314532862","article-title":"Chronic obstructive pulmonary disease exacerbations: Latest evidence and clinical implications","volume":"5","author":"Qureshi","year":"2014","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2147\/COPD.S253812","article-title":"The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline","volume":"15","author":"Kerkhof","year":"2020","journal-title":"COPD"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1007\/s12325-020-01311-3","article-title":"Efficacy of Budesonide\/Glycopyrronium\/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid\/Long-Acting Muscarinic Antagonist\/Long-Acting \u03b22-Agonist (ICS\/LAMA\/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis","volume":"37","author":"Ferguson","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41533-021-00236-w","article-title":"Pulmonary function testing in COPD: Looking beyond the curtain of FEV1","volume":"31","author":"Kakavas","year":"2021","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000448625","article-title":"Predicting Health-Related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease: The Impact of Age","volume":"92","author":"Corlateanu","year":"2016","journal-title":"Respiration"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1183\/09031936.00054213","article-title":"A comparison of the efficacy and safety of once-daily fluticasone furoate\/vilanterol with twice-daily fluticasone propionate\/salmeterol in moderate to very severe COPD","volume":"43","author":"Agusti","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_48","first-page":"250","article-title":"Combination of Fluticasone Furoate and Vilanterol for the Treatment of Chronic Obstructive Pulmonary Disease","volume":"48","author":"Bollmeier","year":"2014","journal-title":"Ann. Pharm."},{"key":"ref_49","first-page":"e92","article-title":"Evolution of the COPD Assessment Test Score during Chronic Obstructive Pulmonary Disease Exacerbations: Determinants and Prognostic Value","volume":"20","author":"Zudaire","year":"2013","journal-title":"Can. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12931-015-0184-8","article-title":"Once-daily fluticasone furoate\/vilanterol 100\/25 mcg versus twice daily combination therapies in COPD\u2014Mixed treatment comparisons of clinical efficacy","volume":"16","author":"Stynes","year":"2015","journal-title":"Respir. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"00634","DOI":"10.1183\/23120541.00634-2020","article-title":"Inhaled therapy reduces COPD mortality","volume":"6","author":"Andreas","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17476348.2020.1816830","article-title":"Evaluating triple ICS\/LABA\/LAMA therapies for COPD patients: A network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies","volume":"15","author":"Calzetta","year":"2021","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1513\/pats.200603-096SS","article-title":"Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease","volume":"3","author":"Sin","year":"2006","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.201508-1647OC","article-title":"Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial","volume":"193","author":"Stone","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/COPD.S170848","article-title":"Status of and strategies for improving adherence to COPD treatment","volume":"14","year":"2019","journal-title":"COPD"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2017.06.007","article-title":"Adherence to COPD treatment: Myth and reality","volume":"129","author":"Rogliani","year":"2017","journal-title":"Respir. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in All-Cause Mortality with Fluticasone Furoate\/Umeclidinium\/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am. J. Respir Crit Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12931-018-0724-0","article-title":"Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study","volume":"19","author":"Bremner","year":"2018","journal-title":"Respir. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"00255","DOI":"10.1183\/23120541.00255-2021","article-title":"Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: A double-blind, randomised controlled trial","volume":"7","author":"Salvi","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.rmed.2019.08.005","article-title":"Ultra-LABAs for the treatment of asthma","volume":"156","author":"Cazzola","year":"2019","journal-title":"Respir. Med."}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/90\/5\/51\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:41:52Z","timestamp":1760143312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/90\/5\/51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["arm90050051"],"URL":"https:\/\/doi.org\/10.3390\/arm90050051","relation":{},"ISSN":["2543-6031"],"issn-type":[{"type":"electronic","value":"2543-6031"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}